Selvigaltin

Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC₅₀ value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis^[1][2][3][4]. IC50 & Target:Gal-3^[1] In Vivo:Selvigaltin (30 mg/kg, p.o., daily for 5 days) reduces the high fat diet (HFD)-induced increase in plasma cholesterol, ALT plasma levels, collagen deposition, fibrosis and normalize plasma triglycerides levels in HFD rabbits^[3].
Selvigaltin (0.3, 1.0, and 5.0 mg/kg, p.o., daily for 4-week) reduces the AST, ALT, bilirubin levels and reduces the HFD-induced increase of several inflammation markers, particularly the mRNA expression of IL6 in HFD rabbits^[3].